Large clinical trials to evaluate risks of testosterone treatment urgently needed

Physicians do not have sufficient information from clinical trials to understand the risks associated with the prescription of testosterone in older men, according to a Comment in The Lancet Diabetes & Endocrinology, written by Professor Stephanie Page, of the University of Washington and Harborview Medical Center, Seattle, USA.

While the benefits of therapy in younger men with a deficiency of the hormone are well established, testosterone is now widely prescribed to , particularly in the USA.

Existing studies have produced conflicting findings over whether the prescription of testosterone is associated with increased cardiovascular risk in older men, and ongoing studies are unlikely to adequately address this question, meaning that even if an appropriately powered trial were to start today, reliable safety data are at least a decade away.

According to Professor Page, "In an era when millions of men are using testosterone every day, support is urgently needed from both the public and medical communities to fund an appropriate clinical study to assess the risks and benefits of testosterone treatment in older men. There is a danger that funding and regulatory agencies will overinterpret the evidence from existing and ongoing observational studies, and conclude that larger and longer are unnecessary and unwarranted. This conclusion would do men's health a disservice."

"Testosterone is a billion dollar industry, probably fuelled partly by direct to consumer advertising and some degree of overprescription," Professor Page adds. "Physicians need to discuss with their patients that we simply do not fully understand the risks associated with testosterone use in older men, and use conservative treatment guidelines – such as those provided by the Endocrine Society – to guide therapeutic decisions."

More information: Paper: www.thelancet.com/journals/lan… (14)70082-8/abstract

add to favorites email to friend print save as pdf

Related Stories

Midrange testosterone levels better for older men

Jan 10, 2014

(Medical Xpress)—Optimal levels of testosterone - meaning neither low nor high - in older men are associated with better survival, according to a study recently published by a team of UWA researchers in ...

Recommended for you

Biomedical team creates 'nerve on a chip'

Dec 24, 2014

Michael J. Moore and J. Lowry Curley first met in the laboratory as professor and student. Now the two Tulane University researchers have started a new biomedical company that's winning praise and awards.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.